DUBLIN – The EMA's Committee for Human Medicinal Products (CHMP) closed out 2017 with recommendations for three new drug approvals and for one new biosimilar, along with positive recommendations for five products approved under the generic, hybrid or informed consent pathways, plus two line extensions.